Lisanti Capital Growth LLC Increases Stake in NewAmsterdam Pharma Company N.V. $NAMS

Lisanti Capital Growth LLC grew its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 278.1% during the 4th quarter, HoldingsChannel reports. The fund owned 179,410 shares of the company’s stock after purchasing an additional 131,965 shares during the period. NewAmsterdam Pharma comprises about 1.5% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 15th largest holding. Lisanti Capital Growth LLC’s holdings in NewAmsterdam Pharma were worth $6,294,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Capital World Investors increased its stake in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the period. Jennison Associates LLC increased its stake in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after buying an additional 1,252,451 shares during the period. Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after buying an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after buying an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc increased its stake in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after buying an additional 393,855 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $35.44 on Friday. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.78 and a 1 year high of $42.21. The firm’s 50-day moving average is $32.76 and its two-hundred day moving average is $34.25. The stock has a market cap of $4.14 billion, a price-to-earnings ratio of -19.80 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million for the quarter. On average, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the transaction, the insider directly owned 69,302 shares in the company, valued at $2,099,850.60. This represents a 60.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael H. Davidson sold 443,707 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer owned 174,144 shares in the company, valued at approximately $5,790,288. The trade was a 71.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,122,805 shares of company stock worth $36,606,033 in the last three months. Corporate insiders own 12.74% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on NAMS shares. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC raised their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Guggenheim raised their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.